2013
Investigation of the Interactions between Methadone and Elvitegravir-Cobicistat in Subjects Receiving Chronic Methadone Maintenance
Bruce RD, Winkle P, Custodio JM, Wei X, Rhee MS, Kearney BP, Ramanathan S, Friedland GH. Investigation of the Interactions between Methadone and Elvitegravir-Cobicistat in Subjects Receiving Chronic Methadone Maintenance. Antimicrobial Agents And Chemotherapy 2013, 57: 6154-6157. PMID: 24080665, PMCID: PMC3837895, DOI: 10.1128/aac.01229-13.Peer-Reviewed Original ResearchConceptsEVG/COBIBaseline valuesEffect of elvitegravirOpioid-dependence therapiesHIV-seronegative subjectsConcentration-time curveChronic methadone maintenanceDependence therapyOpioid withdrawalMethadone pharmacokineticsDosing periodMethadone maintenanceHistorical controlsPharmacodynamic studiesPharmacokinetic parametersMethadoneCobicistatElvitegravirMean areaAUCtauPharmacodynamicsCmaxSubjectsCOBISteady-state evaluationThe Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce RD, Winkle P, Custodio JM, Wei LX, Rhee MS, Kearney BP, Ramanathan S, Friedland GH. The Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 63: 480-484. PMID: 23599011, DOI: 10.1097/qai.0b013e3182961d31.Peer-Reviewed Original ResearchConceptsEVG/COBIBuprenorphine/naloxoneBaseline valuesBuprenorphine/naloxone treatmentEffect of elvitegravirElvitegravir/cobicistatOpioid-dependence therapiesHIV-seronegative subjectsNorbuprenorphine levelsOpioid pharmacodynamicsOpioid withdrawalNaloxone treatmentPharmacodynamic interactionsBuprenorphine/Historical controlsPharmacodynamic studiesAUCtauCobicistatNaloxoneCmaxElvitegravirTherapySubjectsCOBISteady-state evaluationPharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce R, Moody DE, Chodkowski D, Andrews L, Fang WB, Morrison J, Parsons TL, Friedland GH. Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. The American Journal Of Drug And Alcohol Abuse 2013, 39: 80-85. PMID: 23421567, DOI: 10.3109/00952990.2013.764885.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneHuman immuno-deficiency virusBuprenorphine/Buprenorphine/naloxone treatmentAddition of raltegravirOpioid-dependence therapiesHIV-seronegative subjectsEffect of raltegravirOpioid withdrawalNaloxone treatmentPharmacokinetic interactionsNaloxone concentrationsHistorical controlsPharmacodynamic parametersPharmacodynamic studiesBaseline valuesRaltegravirNaloxoneBuprenorphineSignificant differencesTherapySubjectsPrimary metabolitesSteady-state evaluationPatients
2010
Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir
Bruce RD, Altice FL, Moody DE, Morse GD, Andrews L, Lin SN, Fang WB, Ma Q, Friedland GH. Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 54: 511-514. PMID: 20672450, PMCID: PMC4841260, DOI: 10.1097/qai.0b013e3181d3cad3.Peer-Reviewed Original ResearchConceptsLPV/rBuprenorphine/naloxoneHIV-seronegative subjectsLopinavir/ritonavirOpioid withdrawalPharmacokinetic interactionsDaily lopinavir/ritonavirDaily LPV/rSteady-state pharmacokinetic evaluationBuprenorphine pharmacokineticsR administrationDosage modificationNaloxone concentrationsHistorical controlsPharmacodynamic responseAUC0-24hBaseline valuesPharmacokinetic evaluationNaloxonePharmacokinetic studySignificant differencesRitonavirNLXCmaxClearance
1996
Effect of Stavudine on Human Immunodeficiency Virus Type 1 Virus Load as Measured by Quantitative Mononuclear Cell Culture, Plasma RNA, and Immune Complex-Dissociated Antigenemia
Griffith B, Brett-Smith H, Kim G, Mellors J, Chacko T, Garner R, Cheng Y, Alcabes P, Friedland G. Effect of Stavudine on Human Immunodeficiency Virus Type 1 Virus Load as Measured by Quantitative Mononuclear Cell Culture, Plasma RNA, and Immune Complex-Dissociated Antigenemia. The Journal Of Infectious Diseases 1996, 173: 1252-1255. PMID: 8627080, DOI: 10.1093/infdis/173.5.1252.Peer-Reviewed Original ResearchConceptsAntiviral effectHuman immunodeficiency virus type 1Peripheral blood mononuclear cellsImmunodeficiency virus type 1Effects of stavudineWeeks of therapyTime pointsBaseline median valuesBlood mononuclear cellsMononuclear cell culturesVirus type 1Antigen levelsMononuclear cellsPolymerase chain reactionVirus loadPlasma RNAWeek 4Baseline valuesImmune complexesStavudineVirus titersType 1Chain reactionPatientsTherapy